- Home
- KOSS vs LSB Comparison
KOSS vs LSB Comparison
Compare KOSS & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOSS
- LSB
- Stock Information
- Founded
- KOSS 1953
- LSB 2002
- Country
- KOSS United States
- LSB China
- Employees
- KOSS N/A
- LSB N/A
- Industry
- KOSS Consumer Electronics/Appliances
- LSB
- Sector
- KOSS Consumer Staples
- LSB
- Exchange
- KOSS Nasdaq
- LSB NYSE
- Market Cap
- KOSS 62.5M
- LSB 53.6M
- IPO Year
- KOSS N/A
- LSB N/A
- Fundamental
- Price
- KOSS $5.99
- LSB $2.23
- Analyst Decision
- KOSS
- LSB
- Analyst Count
- KOSS 0
- LSB 0
- Target Price
- KOSS N/A
- LSB N/A
- AVG Volume (30 Days)
- KOSS 67.7K
- LSB 7.4K
- Earning Date
- KOSS 01-30-2025
- LSB 12-19-2024
- Dividend Yield
- KOSS N/A
- LSB N/A
- EPS Growth
- KOSS N/A
- LSB N/A
- EPS
- KOSS N/A
- LSB N/A
- Revenue
- KOSS $12,289,961.00
- LSB $79,415,311.00
- Revenue This Year
- KOSS N/A
- LSB $39.33
- Revenue Next Year
- KOSS N/A
- LSB $75.61
- P/E Ratio
- KOSS N/A
- LSB N/A
- Revenue Growth
- KOSS N/A
- LSB N/A
- 52 Week Low
- KOSS $2.27
- LSB $1.88
- 52 Week High
- KOSS $18.73
- LSB $11.20
- Technical
- Relative Strength Index (RSI)
- KOSS 39.58
- LSB 40.56
- Support Level
- KOSS $5.86
- LSB $2.10
- Resistance Level
- KOSS $6.65
- LSB $2.49
- Average True Range (ATR)
- KOSS 0.41
- LSB 0.22
- MACD
- KOSS 0.01
- LSB 0.00
- Stochastic Oscillator
- KOSS 21.43
- LSB 16.35
About KOSS Koss Corporation
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.